9 recruiting, 7 completed, 6 active not recruiting, 5 terminated. 31 Phase 1, 12 Phase 2.
Follow Regn2810: new trials by email Literature Review of Regn2810 trials Research Report on Regn2810
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-08-31 | 2026-05-05 |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-08-10 | 2026-09-09 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers 27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2024-08-06 | 2026-02-03 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy Cemiplimab - Hepatitis B Virus | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-01 | 2023-09-07 | |
| A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab 89Zr˗DFO˗REGN5054, cemiplimab - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | Regeneron Pharmaceuticals | 22 | 2023-02-07 | 2026-10-20 |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Linvoseltamab, Daratumumab, Carfilzomib - Multiple Myeloma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 317 | 2022-08-17 | 2026-11-05 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2021-02-09 | 2023-08-14 |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers REGN7075, Cemiplimab, Platinum-based doublet chemotherapy - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 548 | 2020-12-21 | 2026-07-02 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab REGN5668, Cemiplimab, Ubamatamab - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 612 | 2020-12-08 | 2026-09-24 |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies REGN6569, Cemiplimab - Squamous Cell Carcinoma of Head and Neck | Phase 1 | Terminated | Regeneron Pharmaceuticals | 38 | 2020-10-05 | 2025-02-24 |
| Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Atezolizumab, Avelumab, Cemiplimab - Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm | Phase 1 | Active not recruiting | University of Southern California | 10 | 2020-08-12 | 2026-09-21 |
| Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery - Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma | Phase 1 | Active not recruiting | Emory University | 14 | 2020-05-15 | 2026-09-14 |
| Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART Cemiplimab, Placebo - HIV Infections | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2019-08-13 | 2022-03-02 |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors REGN5678, Cemiplimab - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 345 | 2019-08-12 | 2026-11-04 |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Cemiplimab - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 97 | 2019-04-11 | 2026-01-21 |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated - Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 57 | 2018-09-24 | 2025-04-08 |
Showing 20 of 31. Sign in to see all of them.
Ovarian Neoplasms (4) · Recurrence (4) · Fallopian Tube Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Glioblastoma (2) · Glioma (2) · Lymphoma, B-Cell (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Melanoma (2)
Regeneron Pharmaceuticals (20) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Emory University (1) · Inovio Pharmaceuticals (1) · M.D. Anderson Cancer Center (1) · Palleon Pharmaceuticals, Inc. (1) · University of Southern California (1)
United States (25) · Spain (7) · Netherlands (5) · South Korea (5) · Australia (4) · France (4) · Israel (4) · United Kingdom (4) · Belgium (2) · Brazil (2) · Poland (2) · Austria (1) · Canada (1) · Germany (1) · Greece (1)
Cynthia Gay, MD (1) · Debika Bhattacharya, MD (1) · Gino K In, MD (1) · Jeffrey Skolnik, MD (1) · Jordan Feld, MD, PhD (1) · Joselle Cook, M.B.B.S. (1) · Kah Whye Peng, PhD (1) · Megan Mantica (1) · Michael Lowe, MD (1) · Nora Bennani, M.D. (1) · Nora Bennani, MD (1) · Raymond T. Chung, MD (1) · Timothy A Yap (1)
PMID 35175355, PMID 27879972, PMID 29863979, PMID 32554615, PMID 33146741, PMID 33831732, PMID 33929394, PMID 33942954, PMID 36898933, PMID 38449916, PMID 38900987, PMID 39422598, PMID 39652449
2016 (3), 2015 (2), 2019 (2), 2023 (2), P50CA186781 (2), R01CA262613 (2), 2025 (1), P30CA014089 (1), P30CA138292 (1), UM1CA186690 (1), UM1CA186691 (1)